Spyre Therapeutics, Inc. (SYRE) Tops Q2 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts SYRE Hot Sheet
Join SI Premium – FREE
Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q2 EPS of ($0.36), $0.40 better than the analyst estimate of ($0.76).
For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Putin's Aide Says War In Ukraine Moving Toward An End - Vesti
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Citi on Grab after Taiwan acquisition rejection: 'we view the official rejection as a minor strategic setback'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
